Cellular immune responses to HCV core increase and HCV RNA levels decrease during successful antiretroviral therapy

Gut

Volumn 59, Issue 9, 2010, Pages 1252-1258

  Rohrbach, Janine ^a   Robinson, Nicola ^b   Harcourt, Gillian ^b   Hammond, Emma ^c   Gaudieri, Silvana ^c,d   Gorgievski, Meri ^e,m   Telenti, Amalio ^f   Keiser, Olivia ^e   Günthard, Huldrych F ^g,m   Hirschel, Bernhard ^h,n   Hoffmann, Matthias ⁱ   Bernasconi, Enos ^f,j   Battegay, Manuel ^f,k   Furrer, Hansjakob ^a,l   Klenerman, Paul ^b   Rauch, Andri ^a,c   Boni J ^f   Bucher, H C ^f   Burgisser Ph ^f   Calmy, A ^f   Cattacin, S ^f   Cavassini, M ^f   Dubs, R ^f   Egger, M ^f   Elzi, L ^f   Erb, P ^f   Fischer, M ^f   Flepp, M ^f   Fontana, A ^f   Francioli, P ^f   Fux, C ^m   Hirsch, H ⁿ   Hosli I ⁿ   Kahlert, Ch ⁿ   Kaiser, L ⁿ   Karrer, U ⁿ   Kind, C ⁿ   Klimkait, Th ⁿ   Ledergerber, B ⁿ   Martinetti, G ⁿ   Martinez, B ⁿ   Muller N ⁿ   Nadal, D ⁿ   Opravil, M ⁿ   Paccaud, F ⁿ   Pantaleo, G ⁿ   Regenass, S ⁿ   Rickenbach, M ⁿ   Rudin, C ^m   Schmid, P ^m   Schultze, D ^m   Schupbach J ^m   Speck, R ^m   Taffe P ^m   Tarr, P ^m   Trkola, A ^m   Vernazza, P ^m   Weber, R ^m   Yerly, S ^m   more..

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c MURDOCH UNIVERSITY   (Australia)

^d UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^e UNIVERSITY OF BERN   (Switzerland)

^f LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^g UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^h GENEVA UNIVERSITY HOSPITALS   (Switzerland)

ⁱ CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^j REGIONAL HOSPITAL OF LUGANO   (Switzerland)

^k UNIVERSITY HOSPITAL BASEL   (Switzerland)

^l Clinical and Laboratory Committee   (Switzerland)

^m SHCS Centre Hospitalier Universitaire Vaudois ^*

ⁿ Data Center   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS RNA; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CORE PROTEIN; GAMMA INTERFERON; HEPATITIS C ANTIGEN;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; COMBINATION ANTIRETROVIRAL THERAPY; DISEASE COURSE; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; VIRUS CORE; BIOSYNTHESIS; BLOOD; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; COHORT ANALYSIS; COMPLICATION; DRUG EFFECTS; GENETICS; HEPACIVIRUS; HEPATITIS C, CHRONIC; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; IMMUNOLOGY; ISOLATION AND PURIFICATION; LONGITUDINAL STUDY; MULTICENTER STUDY; T LYMPHOCYTE; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; FEMALE; HEPACIVIRUS; HEPATITIS C ANTIGENS; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; IMMUNITY, CELLULAR; INTERFERON-GAMMA; LONGITUDINAL STUDIES; MALE; RNA, VIRAL; T-LYMPHOCYTES; VIRAL CORE PROTEINS; VIRAL LOAD;

EID: 77956115889     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gut.2009.205971     Document Type: Article

References (47)

1. Sulkowski MS, Thomas DL. Hepatitis C in the HIV-Infected Person. Ann Intern Med 2003;138:197-207.
2. Rauch A, Rickenbach M, Weber R, et al. Unsafe sex and increased incidence of hepatitis C virus infection among HIV-infected men who have sex with men: the Swiss HIV Cohort Study. Clin Infect Dis 2005;41:395-402. (Pubitemid 41022120)
3. Graham CS, Baden LR, Yu E, et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis 2001;33:562-9.
4. Thomas DL, Astemborski J, Vlahov D, et al. Determinants of the quantity of hepatitis C virus RNA. J Infect Dis 2000;181:844-51.
5. Thomas DL. The challenge of hepatitis C in the HIV-infected person. Annu Rev Med 2008;59:473-85.
6. Rauch A, Gaudieri S, Evison J, et al. Low current and nadir CD4+ T cell counts are associated with higher hepatitis C virus RNA levels in the Swiss HIV cohort study. Antivir Ther 2008;13:455-60.
7. Klenerman P, Lucas M, Barnes E, et al. Immunity to hepatitis C virus: stunned but not defeated. Microbes Infect 2002;4:57-65. (Pubitemid 34127992)
8. Kim AY, Schulze zur Wiesch J, Kuntzen T, et al. Impaired hepatitis C virus-specific T cell responses and recurrent hepatitis C virus in HIV coinfection. PLoS Med 2006;3:e492.
9. Harcourt G, Gomperts E, Donfield S, et al. Diminished frequency of hepatitis C virus specific interferon gamma secreting CD4+ T cells in human immunodeficiency virus/hepatitis C virus coinfected patients. Gut 2006;55:1484-7.
10. Lauer GM, Barnes E, Lucas M, et al. High resolution analysis of cellular immune responses in resolved and persistent hepatitis C virus infection. Gastroenterology 2004;127:924-36.
11. Kim AY, Lauer GM, Ouchi K, et al. The magnitude and breadth of hepatitis C virus-specific CD8+ T cells depend on absolute CD4+ T cell count in individuals coinfected with HIV-1. Blood 2005;105:1170-8.
12. Dutoit V, Ciuffreda D, Comte D, et al. Differences in HCV-specific T cell responses between chronic HCV infection and HIV/HCV co-infection. Eur J Immunol 2005;35:3493-504.
13. Thein HH, Yi Q, Dore GJ, et al. Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis. AIDS 2008;22:1979-91.
14. Qurishi N, Kreuzberg C, Luchters G, et al. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet 2003;362:1708-13.
15. Braitstein P, Palepu A, Dieterich D, et al. Special considerations in the initiation and management of antiretroviral therapy in individuals coinfected with HIV and hepatitis C. AIDS 2004;18:2221-34. (Pubitemid 39620214)
16. Rutschmann OT, Negro F, Hirschel B, et al. Impact of treatment with human immunodeficiency virus (HIV) protease inhibitors on hepatitis C viremia in patients coinfected with HIV. J Infect Dis 1998;177:783-5.
17. Cooper CL, Cameron DW. Review of the effect of highly active antiretroviral therapy on hepatitis C virus (HCV) RNA levels in human immunodeficiency virus and HCV coinfection. Clin Infect Dis 2002;35:873-9.
18. Ledergerber B, Egger M, Opravil M, et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study. Lancet 1999;353:863-8.
19. Schoeni-Affolter FRM, Furrer HJ, Rudin C, et al. COHORT PROFILE: The Swiss HIV Cohort Study. Int J Epidemiol 2009:1-11.
20. Fleming VM, Harcourt G, Barnes E, et al. Virologic footprint of CD4+ T cell responses during chronic HCV infection. J Gen Virol 2010:1396-406.
21. Semmo N, Day CL, Ward SM, et al. Preferential loss of IL-2-secreting CD4+ T helper cells in chronic HCV infection. Hepatology 2005;41:1019-28.
22. Semmo N, Krashias G, Willberg C, et al. Analysis of the relationship between cytokine secretion and proliferative capacity in hepatitis C virus infection. J Viral Hepat 2007;14:492-502. (Pubitemid 46944474)
23. Danta M, Semmo N, Fabris P, et al. Impact of HIV on host-virus interactions during early hepatitis C virus infection. J Infect Dis 2008;197:1558-66.
24. Schnuriger A, Dominguez S, Guiguet M, et al. Acute hepatitis C in HIV-infected patients: rare spontaneous clearance correlates with weak memory CD4 T cell responses to hepatitis C virus. AIDS 2009;23:2079-89.
25. Castelain S, Descamps V, Thibault V, et al. TaqMan amplification system with an internal positive control for HCV RNA quantitation. J Clin Virol 2004;31:227-34.
26. Williams RL. A note on robust variance estimation for cluster-correlated data. Biometrics 2000;56:645-6.
27. Simmonds P. Genetic diversity and evolution of hepatitis C virus - 15 years on. J Gen Virol 2004;85:3173-88. (Pubitemid 39445434)
28. Neumann-Haefelin C, Frick DN, Wang JJ, et al. Analysis of the evolutionary forces in an immunodominant CD8 epitope in hepatitis C virus at a population level. J Virol 2008;82:3438-51.
29. Neumann-Haefelin C, Timm J, Schmidt J, et al. Protective effect of human leukocyte antigen B27 in hepatitis C virus infection requires the presence of a genotype-specific immunodominant CD8+ T cell epitope. Hepatology 2010;51:54-62.
30. Thimme R, Neumann-Haefelin C, Boettler T, et al. Adaptive immune responses to hepatitis C virus: from viral immunobiology to a vaccine. Biol Chem 2008;389:457-67.
31. Rauch A, James I, Pfafferott K, et al. Divergent adaptation of hepatitis C virus genotypes 1 and 3 to human leukocyte antigen-restricted immune pressure. Hepatology 2009;50:1017-29.
32. Fitzmaurice K, Klenerman P. Cellular immunity and acute hepatitis C infection. Curr Pharm Des 2008;14:1666-77.
33. Barnes E, Ward SM, Kasprowicz VO, et al. Ultra-sensitive class I tetramer analysis reveals previously undetectable populations of antiviral CD8+ T cells. Eur J Immunol 2004;34:1570-7.
34. Gaudieri S, Rauch A, Park LP, et al. Evidence of viral adaptation to HLA class I-restricted immune pressure in chronic hepatitis C virus infection. J Virol 2006;80:11094-104.
35. Timm J, Li B, Daniels MG, et al. Human leukocyte antigen-associated sequence polymorphisms in hepatitis C virus reveal reproducible immune responses and constraints on viral evolution. Hepatology 2007;46:339-49.
36. Falconer K, Gonzalez VD, Reichard O, et al. Spontaneous HCV clearance in HCV/HIV-1 coinfection associated with normalized CD4 counts, low level of chronic immune activation and high level of T cell function. J Clin Virol 2008;41:160-3.
37. Fialaire P, Payan C, Vitour D, et al. Sustained disappearance of hepatitis C viremia in patients receiving protease inhibitor treatment for human immunodeficiency virus infection. J Infect Dis 1999;180:574-5.
38. Torti C, Barnes E, Quiros-Roldan E, et al. Suppression of hepatitis C virus replication is maintained long term following HAART therapy, in an individual with HCV/HIV co-infection. Antivir Ther 2004;9:139-42. (Pubitemid 38313957)
39. Weissbrich B, Langmann P, Schubert J, et al. Resolution of HCV infection in a HIV-infected patient under HAART after several hepatitis flare-ups. Eur J Med Res 2003;8:495-8.
40. Zeitoun JD, Mallet V, Chaix ML, et al. Stable recovery from HCV in HIV-HCV co-infection under antiretroviral therapy. J Clin Virol 2007;40:71-3.
41. Yokozaki S, Takamatsu J, Nakano I, et al. Immunologic dynamics in hemophiliac patients infected with hepatitis C virus and human immunodeficiency virus: influence of antiretroviral therapy. Blood 2000;96:4293-9.
42. Hammer SM, Eron JJ Jr, Reiss P, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 2008;300:555-70.
43. Clumeck N, Pozniak A, Raffi F. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of HIV-infected adults. HIV Med 2008;9:65-71.
44. Hisada M, Chatterjee N, Kalaylioglu Z, et al. Hepatitis C virus load and survival among injection drug users in the United States. Hepatology 2005;42:1446-52.
45. De Moliner L, Pontisso P, De Salvo GL, et al. Serum and liver HCV RNA levels in patients with chronic hepatitis C: correlation with clinical and histological features. Gut 1998;42:856-60. (Pubitemid 28277229)
46. Lagging LM, Garcia CE, Westin J, et al. Comparison of serum hepatitis C virus RNA and core antigen concentrations and determination of whether levels are associated with liver histology or affected by specimen storage time. J Clin Microbiol 2002;40:4224-9.
47. Kau A, Vermehren J, Sarrazin C. Treatment predictors of a sustained virologic response in hepatitis B and C. J Hepatol 2008;49:634-51.